# Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A

> **NCT00782470** · — · COMPLETED · sponsor: **Bayer** · enrollment: 38 (actual)

## Conditions studied

- Hematologic Disease
- Blood Coagulation Disorders

## Interventions

- **BEHAVIORAL:** Recombinant Factor VIII (Kogenate, BAY 14-2222)
- **BEHAVIORAL:** Recombinant Factor VIII (Kogenate, BAY 14-2222)
- **BEHAVIORAL:** Recombinant Factor VIII (Kogenate, BAY 14-2222)

## Key facts

- **NCT ID:** NCT00782470
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2014-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00782470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00782470, "Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00782470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*